Squarepoint’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-60,472
| Closed | -$69.5K | – | 4674 |
|
|
2025
Q4 | $69.5K | Buy |
60,472
+1,796
| +3% | +$2.47K | ﹤0.01% | 4093 |
|
|
2025
Q3 | $79.2K | Sell |
58,676
-36,941
| -39% | -$41.9K | ﹤0.01% | 4155 |
|
|
2025
Q2 | $90.4K | Sell |
95,617
-99,792
| -51% | -$64.7K | ﹤0.01% | 4195 |
|
|
2025
Q1 | $90K | Buy |
+195,409
| New | +$123K | ﹤0.01% | 4245 |
|
|
2024
Q4 | – | Sell |
-188,842
| Closed | -$296K | – | 5313 |
|
|
2024
Q3 | $296K | Buy |
+188,842
| New | +$336K | ﹤0.01% | 3454 |
|
|
2023
Q4 | – | Sell |
-62,243
| Closed | -$67.8K | – | 4279 |
|
|
2023
Q3 | $67.8K | Buy |
+62,243
| New | +$109K | ﹤0.01% | 3607 |
|
|
2023
Q2 | – | Sell |
-23,938
| Closed | -$58.2K | – | 3824 |
|
|
2023
Q1 | $58.2K | Sell |
23,938
-3,326
| -12% | -$7.62K | ﹤0.01% | 3039 |
|
|
2022
Q4 | $52.1K | Buy |
+27,264
| New | +$58K | ﹤0.01% | 3053 |
|
|
2022
Q2 | – | Sell |
-26,189
| Closed | -$55K | – | 3169 |
|
|
2022
Q1 | $55K | Sell |
26,189
-12,576
| -32% | -$34.9K | ﹤0.01% | 2672 |
|
|
2021
Q4 | $153K | Buy |
38,765
+26,451
| +215% | +$128K | ﹤0.01% | 2807 |
|
|
2021
Q3 | $59K | Sell |
12,314
-438
| -3% | -$1.8K | ﹤0.01% | 2752 |
|
|
2021
Q2 | $59K | Sell |
12,752
-74,745
| -85% | -$360K | ﹤0.01% | 3093 |
|
|
2021
Q1 | $514K | Buy |
87,497
+71,858
| +459% | +$498K | ﹤0.01% | 1993 |
|
|
2020
Q4 | $53K | Sell |
15,639
-152,515
| -91% | -$291K | ﹤0.01% | 2800 |
|
|
2020
Q3 | $242K | Buy |
168,154
+29,239
| +21% | +$52.1K | ﹤0.01% | 1968 |
|
|
2020
Q2 | $277K | Sell |
138,915
-122,614
| -47% | -$240K | ﹤0.01% | 1647 |
|
|
2020
Q1 | $510K | Buy |
261,529
+155,640
| +147% | +$463K | 0.01% | 1028 |
|
|
2019
Q4 | $439K | Buy |
+105,889
| New | +$408K | ﹤0.01% | 1842 |
|
|
2019
Q3 | – | Sell |
-54,999
| Closed | -$346K | – | 2540 |
|
|
2019
Q2 | $346K | Sell |
54,999
-19,654
| -26% | -$118K | ﹤0.01% | 1864 |
|
|
2019
Q1 | $415K | Buy |
74,653
+48,660
| +187% | +$296K | ﹤0.01% | 1585 |
|
|
2018
Q4 | $173K | Buy |
+25,993
| New | +$211K | ﹤0.01% | 1727 |
|
|
2018
Q2 | – | Sell |
-19,928
| Closed | -$171K | – | 1925 |
|
|
2018
Q1 | $171K | Buy |
+19,928
| New | +$184K | ﹤0.01% | 1521 |
|
|
2017
Q4 | – | Sell |
-14,556
| Closed | -$179K | – | 2234 |
|
|
2017
Q3 | $179K | Sell |
14,556
-1,960
| -12% | -$28.9K | ﹤0.01% | 1418 |
|
|
2017
Q2 | $272K | Buy |
+16,516
| New | +$256K | 0.01% | 1174 |
|
|
2016
Q4 | – | Sell |
-10,800
| Closed | -$195K | – | 1847 |
|
|
2016
Q3 | $195K | Buy |
+10,800
| New | +$174K | 0.01% | 898 |
|
|
2016
Q2 | – | Sell |
-17,980
| Closed | -$215K | – | 1248 |
|
|
2016
Q1 | $215K | Sell |
17,980
-8,520
| -32% | -$89.3K | 0.02% | 970 |
|
|
2015
Q4 | $353K | Buy |
+26,500
| New | +$326K | 0.04% | 719 |
|
Other funds holding LXRX
AG
SL
SC
VCM
Squarepoint's LXRX Position: Q1 2026 in Review
Squarepoint sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2026, closing a stake of 60,472 shares — an estimated $69.5K sold.
Squarepoint first reported a position in LXRX in Q4 2015 and held it in 27 quarters. The position peaked at $514K in Q1 2021. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.
- Squarepoint reported no remaining Lexicon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Squarepoint sold 60,472 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $69.5K.
- Squarepoint first reported a position in Lexicon Pharmaceuticals in Q4 2015 and held it in 27 quarters.
- Squarepoint's Lexicon Pharmaceuticals position peaked at $514K in Q1 2021.
- 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.